Physician profile
Michael A Samuel
NPI 1730175670
$2,787.64
in general payments reported to CMS, 2019-2025
22 companies · $695 in 2025
The $695 reported for 2025 was more than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $306 · 2020: $231 · 2021: $438 · 2022: $552 · 2023: $99.18 · 2024: $467 · 2025: $695.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,261.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,260.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $475.16 | 2020-2024 | Yutiq, Iluvien |
| Heru, INC. | $404.84 | 2022 | |
| Amgen INC. | $331.59 | 2025 | Tepezza |
| Genentech USA, INC. | $307.76 | 2019-2023 | Vabysmo |
| Mallinckrodt Hospital Products INC. | $224.69 | 2021-2022 | |
| Rxsight INC | $210.94 | 2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $189.58 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $174.35 | 2024 | Stellaris |
| Astellas Pharma US INC | $165.48 | 2024-2025 | Izervay |
| Abbvie INC. | $99.07 | 2025 | |
| Novartis Pharmaceuticals Corporation | $83.89 | 2019-2020 | |
| Carl Zeiss Meditec USA, INC. | $29.83 | 2022 | |
| Heidelberg Engineering, INC. | $25.54 | 2019 | |
| Apellis Pharmaceuticals, INC. | $24.61 | 2022 | |
| Alcon Vision LLC | $21.54 | 2025 | Rocklatan |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optos, INC. | $18.77 | 2021 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Samuel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.